Corium International (Corium International) Interest Expense : $-10.03 Mil (TTM As of Jun. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Corium International Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Corium International's interest expense for the three months ended in Jun. 2018 was $ -3.37 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2018 was $-10.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Corium International's Operating Income for the three months ended in Jun. 2018 was $ -9.99 Mil. Corium International's Interest Expense for the three months ended in Jun. 2018 was $ -3.37 Mil. Corium International did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Corium International Interest Expense Historical Data

The historical data trend for Corium International's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corium International Interest Expense Chart

Corium International Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Interest Expense

Get a 7-Day Free Trial

-7.71

-6.96

-7.45

-7.95

-8.30

Corium International Quarterly Data
	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18
Interest Expense	Get a 7-Day Free Trial															-2.09	-2.13	-2.12	-2.41	-3.37

Corium International Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.03 Mil.

Corium International (NAS:CORI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Corium International's Interest Expense for the three months ended in Jun. 2018 was $-3.37 Mil. Its Operating Income for the three months ended in Jun. 2018 was $-9.99 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2018 was $70.36 Mil.

Corium International's Interest Coverage for the quarter that ended in Jun. 2018 is calculated as

Corium International did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Corium International (Corium International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corium International Inc (NAS:CORI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.coriumgroup.com

Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.

Executives

Essex Woodlands Health Ventures Fund Vii Lp	10 percent owner	21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Robert S Breuil	officer: Chief Financial Officer	2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Bhaskar Chaudhuri	director	ONE ENTERPRISE, ALISO VIEJO CA 92656
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Ronald W Eastman	director, 10 percent owner	335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Paul Goddard	director	ADOLOR CORPORATION, 700 PENNSYLVANIA DR., EXTON PA 19341
David Greenwood	director	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Ivan P. Gergel	director	C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO CA 94158
Peter D Staple	director, officer: President & CEO	863 C MITTEN ROAD, BURLINGAME CA 94010
Joseph J. Sarret	officer: Chief Business Officer	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003